Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFYWE3)

Drug Name

CD-832.HCL Drug Info

Synonyms

129904-55-8; 2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 5-(3-nitrooxypropyl) 3-[2-(3-pyridylcarbonylamino)ethyl] diester monohydrochloride; CD-832.HCl

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 179844
CAS Number: CAS 129904-55-8
TTD Drug ID: DMFYWE3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[2]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[3]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[4]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[5]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[6]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[7]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[7]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[8]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[9]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[1]

------------------------------------------------------------------------------------

References

1	Actions of a new Ca2+ channel antagonist, CD832, on two types of Ca2+ channels in smooth muscle. Eur J Pharmacol. 1994 Feb 11;252(3):267-74.
2	Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
3	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
4	RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
5	Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
6	Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.